Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716871 | 0.90 | TK1 (0.37) | TK1BCHETOP2A | |
| SCHEMBL13722465 | 0.84 | TDP1 (0.32) | — | |
| SCHEMBL16661547 | 0.83 | TK1 (0.35) | TK1BCHERNASE1NT5MTOP2A | |
| SCHEMBL19261579 | 0.83 | TK1 (0.35) | TK1BCHERNASE1NT5MTOP2A | |
| SCHEMBL16772712 | 0.83 | TK1 (0.35) | TK1BCHERNASE1NT5MTOP2A | |
| SCHEMBL16648780 | 0.83 | TK1 (0.35) | TK1BCHERNASE1NT5MTOP2A | |
| SCHEMBL1058381 | 0.83 | TK1 (0.37) | TK1BCHERNASE1NT5M | |
| SCHEMBL28618584 | 0.83 | TK1 (0.39) | TK1BCHERNASE1NT5M | |
| SCHEMBL28618582 | 0.83 | TK1 (0.39) | TK1BCHERNASE1NT5M | |
| SCHEMBL5696121 | 0.83 | TK1 (0.39) | TK1BCHERNASE1NT5M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1013661-B2 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2018-10-24 | — | — | EP | disclosed |
| EP-2361921-B1 | Bicyclo-oligonucleotide analogues | EXIQON AS (DK) | 2015-06-03 | — | — | EP | disclosed |
| EP-2295441-B1 | Bicyclonucleoside Oligonucleotide Analogue | EXIQON AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| US-RE44779-E1 | Bicyclonucleoside and oligonucleotide analogues | SANTARIS PHARMA A/S (DK) | 2014-02-25 | — | — | US | disclosed |
| EP-1013661-B1 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2012-01-18 | — | — | EP | disclosed |
| EP-2361921-A2 | Novel bicyclonucleoside and oligonnucleotide analogue | Exiqon A/S (DK) | 2011-08-31 | — | — | EP | disclosed |
| EP-2295441-A2 | Novel Bicyclonucleoside and Oligonucleotide Analogue | Exiqon A/S (DK) | 2011-03-16 | — | — | EP | disclosed |
| US-6770748-B2 | ANTISENSE AGENTS FOR AIDS; IMMOBILIZED CONFORMATION OF THE SUGAR PORTION OF NUCLEIC ACID | Imanishi, Takeshi (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | TAKESHI IMANISHI (JP) | 2003-06-05 | — | — | US | disclosed |
| US-6268490-B1 | NUCLEOSIDE ANALOG; FOR ANTISENSE AGENT WHICH IS HYDROLASE RESISTANT, HAS HIGH SENSE STRAND BINDING ABILITY AND IS EASILY SYNTHESIZED | TAKESHI IMANISHI (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1013661-A1 | NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUES | Imanishi, Takeshi (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | DCLRE1B, POLA1, POLB | TK1 16/4885BCHE 933/4885RNASE1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.